UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs

Wei Jin; Yang Liu; Si Guang Xu; Wen Jin Yin; Jun Jie Li; Jin Ming Yang; Zhi Ming Shao

doi:10.1007/s10549-009-0683-8

UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs

Wei Jin, Yang Liu, Si Guang Xu, Wen Jin Yin, Jun Jie Li, Jin Ming Yang, Zhi Ming Shao

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Overexpression of MDR1 in breast cancer remains a major cause for the failure of chemotherapy. In the present report, we find UHRF1 plays an important role in inhibiting MDR1 promoter activity by directly binding to the MDR1 promoter. Knockdown of UHRF1 activates MDR1 promoter activity and expression, attenuates the binding of UHRF1 and HDAC1 to the MDR1 promoter. Overexpression of UHRF1 in NCI/ADR-RES cells can induce deacetylation of histones H3 and H4 on the MDR1 promoter, which is facilitated by recruitment of HDAC1 to the MDR1 promoter. Loss of histone acetylation is accompanied by loss of binding of the key transcription factor, MyoD, CBP and p300, locking in marked suppression of MDR1, increasing sensitivity of MDR cancer cells to cytotoxic drugs that are transported by P-glycoprotein (P-gp). The inhibition of MDR1 expression by UHRF1 may provide potential ways to overcome multidrug resistance (MDR) in breast cancer treatment.

Original language	English
Pages (from-to)	39-48
Number of pages	10
Journal	Breast Cancer Research and Treatment
Volume	124
Issue number	1
DOIs	https://doi.org/10.1007/s10549-009-0683-8
State	Published - Nov 2010

Bibliographical note

Funding Information:
Acknowledgments This study was supported by the grants from the Innovation Program of Shanghai Municipal Education Commission (No. 09ZZ04); the Natural Science Foundation of Shanghai (No. 09ZR1406900); and Shanghai Pujiang Program and Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry.

Keywords

Histone modification
MDR1
Multidrug resistance
UHRF1

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-009-0683-8

Cite this

@article{3a4f5014117349059c513210d528ed8e,

title = "UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs",

abstract = "Overexpression of MDR1 in breast cancer remains a major cause for the failure of chemotherapy. In the present report, we find UHRF1 plays an important role in inhibiting MDR1 promoter activity by directly binding to the MDR1 promoter. Knockdown of UHRF1 activates MDR1 promoter activity and expression, attenuates the binding of UHRF1 and HDAC1 to the MDR1 promoter. Overexpression of UHRF1 in NCI/ADR-RES cells can induce deacetylation of histones H3 and H4 on the MDR1 promoter, which is facilitated by recruitment of HDAC1 to the MDR1 promoter. Loss of histone acetylation is accompanied by loss of binding of the key transcription factor, MyoD, CBP and p300, locking in marked suppression of MDR1, increasing sensitivity of MDR cancer cells to cytotoxic drugs that are transported by P-glycoprotein (P-gp). The inhibition of MDR1 expression by UHRF1 may provide potential ways to overcome multidrug resistance (MDR) in breast cancer treatment.",

keywords = "Histone modification, MDR1, Multidrug resistance, UHRF1",

author = "Wei Jin and Yang Liu and Xu, {Si Guang} and Yin, {Wen Jin} and Li, {Jun Jie} and Yang, {Jin Ming} and Shao, {Zhi Ming}",

note = "Funding Information: Acknowledgments This study was supported by the grants from the Innovation Program of Shanghai Municipal Education Commission (No. 09ZZ04); the Natural Science Foundation of Shanghai (No. 09ZR1406900); and Shanghai Pujiang Program and Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry.",

year = "2010",

month = nov,

doi = "10.1007/s10549-009-0683-8",

language = "English",

volume = "124",

pages = "39--48",

number = "1",

}

TY - JOUR

T1 - UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs

AU - Jin, Wei

AU - Liu, Yang

AU - Xu, Si Guang

AU - Yin, Wen Jin

AU - Li, Jun Jie

AU - Yang, Jin Ming

AU - Shao, Zhi Ming

N1 - Funding Information: Acknowledgments This study was supported by the grants from the Innovation Program of Shanghai Municipal Education Commission (No. 09ZZ04); the Natural Science Foundation of Shanghai (No. 09ZR1406900); and Shanghai Pujiang Program and Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry.

PY - 2010/11

Y1 - 2010/11

N2 - Overexpression of MDR1 in breast cancer remains a major cause for the failure of chemotherapy. In the present report, we find UHRF1 plays an important role in inhibiting MDR1 promoter activity by directly binding to the MDR1 promoter. Knockdown of UHRF1 activates MDR1 promoter activity and expression, attenuates the binding of UHRF1 and HDAC1 to the MDR1 promoter. Overexpression of UHRF1 in NCI/ADR-RES cells can induce deacetylation of histones H3 and H4 on the MDR1 promoter, which is facilitated by recruitment of HDAC1 to the MDR1 promoter. Loss of histone acetylation is accompanied by loss of binding of the key transcription factor, MyoD, CBP and p300, locking in marked suppression of MDR1, increasing sensitivity of MDR cancer cells to cytotoxic drugs that are transported by P-glycoprotein (P-gp). The inhibition of MDR1 expression by UHRF1 may provide potential ways to overcome multidrug resistance (MDR) in breast cancer treatment.

AB - Overexpression of MDR1 in breast cancer remains a major cause for the failure of chemotherapy. In the present report, we find UHRF1 plays an important role in inhibiting MDR1 promoter activity by directly binding to the MDR1 promoter. Knockdown of UHRF1 activates MDR1 promoter activity and expression, attenuates the binding of UHRF1 and HDAC1 to the MDR1 promoter. Overexpression of UHRF1 in NCI/ADR-RES cells can induce deacetylation of histones H3 and H4 on the MDR1 promoter, which is facilitated by recruitment of HDAC1 to the MDR1 promoter. Loss of histone acetylation is accompanied by loss of binding of the key transcription factor, MyoD, CBP and p300, locking in marked suppression of MDR1, increasing sensitivity of MDR cancer cells to cytotoxic drugs that are transported by P-glycoprotein (P-gp). The inhibition of MDR1 expression by UHRF1 may provide potential ways to overcome multidrug resistance (MDR) in breast cancer treatment.

KW - Histone modification

KW - MDR1

KW - Multidrug resistance

KW - UHRF1

UR - http://www.scopus.com/inward/record.url?scp=77957705615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957705615&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0683-8

DO - 10.1007/s10549-009-0683-8

M3 - Article

C2 - 20037778

AN - SCOPUS:77957705615

SN - 0167-6806

VL - 124

SP - 39

EP - 48

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this